These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21857779)

  • 1. Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.
    La Piana GE; Corda L; Bertella E; Montemurro LT; Pini L; Tantucci C
    Int J Chron Obstruct Pulmon Dis; 2011; 6():399-405. PubMed ID: 21857779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
    Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
    Cazzola M; Paggiaro P; Palange P; Bjermer L; Ausin P; Carlsson LG; Ekelund J; Lotvall J
    Clin Drug Investig; 2012 Mar; 32(3):147-55. PubMed ID: 22235841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE; Tashkin DP; Kerwin E; Knorr BA; Shekar T; Banerjee S; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.
    Whale CI; Sovani MP; Mortimer KJ; Harrison TW; Tattersfield AE
    Br J Clin Pharmacol; 2008 Jun; 65(6):841-7. PubMed ID: 18394012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
    Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Banerjee S; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():43-55. PubMed ID: 22334768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
    van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
    Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.
    D'Urzo AD; De Salvo MC; Ramirez-Rivera A; Almeida J; Sichletidis L; Rapatz G; Kottakis J;
    Chest; 2001 May; 119(5):1347-56. PubMed ID: 11348938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
    Benhamou D; Cuvelier A; Muir JF; Leclerc V; Le Gros V; Kottakis J; Bourdeix I
    Respir Med; 2001 Oct; 95(10):817-21. PubMed ID: 11601748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M; Rogliani P; Ruggeri P; Segreti A; Proietto A; Picciolo S; Matera MG
    Respir Med; 2013 Jun; 107(6):848-53. PubMed ID: 23490225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
    Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.
    Rossi A; Kristufek P; Levine BE; Thomson MH; Till D; Kottakis J; Della Cioppa G;
    Chest; 2002 Apr; 121(4):1058-69. PubMed ID: 11948033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.